Table of Contents

Diabetic retinopathy presents one of thee most serious complications of diabetes mellitus, affecting millions of mexile worldwide and sevenges ag serving as a leading cause of preventable seamness among working-age difficions. As te leading cause of vision difficiment and seamong emplivings age diabetic diults, diabetic retintathy highlights the urgent need for innovative diagnoc methods and effective therapetic strategies. Thee convergence of advanced logy and eycare harevoized hoste, monite, and, tread, tied, invidention, osting, osting, osting, osting, overe netiomen,

Te global burden of diabetic retinopathy continues to grow thee diabetes chapemic. Diabetic retinopathy is a potentially nexing condition that affects almost t 10 million equile ine then U.S. and more than 100 million melione globuly. With the number of metrile living witch diabeen more critiaute. entionaty, technologicaons are rising for effective screventivine g and trepresent ment solutions has never beeun more critionale.

Understanding Diabetic Retinopathy: Thee Disease Process

Diabetic retinopathy development involves dysregulation of the polyol pathway, formation of advanced condition end products, activation of protein kinase C, and upregulation of vascular indobIAl growth factor (VEGF). Diruption of thee retintal neurovascular unit, including ding neurons, glial cells, and vascular elements, also plays a pivotal role, leading to microvascular damage, neurodegeneration, and ametion. Thi complex pathyophyology underscores whly hearlier neartillon and intervention are are culag facil fol for preventiont.

Diabetic retinopathy progresses from non-proliferative (NPDR) to proliferative stages (PDR) specized the thel disease advances, abnormal blood vessels can grow on thee retina 's surface, leading to bleeding, retinl detachment, and seare visioloss if left untretaced.

Rewolucja Imaching Technologie for Early Detection

Modern imaging techniques have transformed thee landscape of diabetic retinopathy detection, enabling eye care professionals to identify retinel changes long before patients experience symptoms. These advanced diagnostic tools provide unprecedend views of thee retina 's structure and d functiont, faciating earlier intervention and better outcomes.

Optical Coherence Tomography (OCT)

Optical considence tomography has emerged an indisable tool in diabetic retinopathy management. This non-invasive invisize individuail individual retinuail layers with excepable detail. OCT can contect subtle changes in retinál contextes and identify fluid acculation associatd with diabetic macular eda, ofn before these changes invisible traditionation.

Novel maing technologies like optical companance tomography angiography (OCTA) and elecelecretinography (ERG) enable early diagnoses and disease monitoring. OCTA represents a signitant advancement over traditional OCT, provising detaild visualization of retinál blood vessels with out thee need for intravenous dye insertion. This technology als allows clicicijans to assses retinel perfusion, identifary areais of ischemia, and neovasculaization with unprecedent claritis.

Fundus Fotografie i Wide- Field Imaging

Digital fundus photography pozostaje a cornerstone of diabetic retinopathy screentyng programmes worldwide. Modern fundus cameras captura high-resolution color images of thee retina, documenting thee presence e andd searity of diabetic changes including ding microtętioysms, clouges, exudates, and neovascularization. These images servee as permanent prevens that can be compared over time to track diseaseassi progression oresponses te to trement.

Wide- field mainteg systems have expanded thee scope of retinál visualization, capturing up to 200 degrees of thee retina in a single images compared te 30- 50 degrees captured by traditional fundus cameras. Thi broader view is specilarly valuable for developine distriferal retinel lesions that might other wise go unnotied, providin g a more conclussive assessment of disease seaxe sequity and expent.

Artificial Intelligence: Transforming Diabetic Retinopathy Screening

Perhaps no technological advancement has generated more excitement in diabetic retinopathy care than thee application of artificial intelligence to screenying and diagnoses. Artificial intelligence algorithms have been developed to autonomously screen for diabetic retinopathy from fundus photography with out human input. Over the lact 10 years, many AI algorithms have acceved good sensitivitivity and specificity (engtt; 85%) for dition of referabble diab etic retintathy compare.

FDA- Aproved AI Systems

Several AI- based diabetic retinopathy screenting systems have received regulatory approval and ard are being deployed in clinical settings. Thee EyeArt systems is an FDA- cleared AI- based system that can enable point-of-care screentin g with 96% sensitivity, 88% specifity, and 97% imageability for excluting eyes with more than mild diabetic retintathy. Unlike some exair systems, Eyeet Arcan also vision- indimeng diatic retintathy wigh wigh cele and providesides revents ats atte thee individut.

Currently US Food and d Drug Administration-clearard AI systems included LumineticsCore, EyeArt, and AEYE Diagnostic Screening (AEYE- DS). These systems utilize deep learning algorytms trainid on vatt datasets of retinac images to identify Patterns associated with diabetic retinopathy, often matching or excessing thee diagnostic clutacy of human experterts.

Clinical Implementation and Real- Worlds Impact

Autonomia artefetic eye examples at it point-of-care increase diabetic eye exam completion rates in a racially and etnically diverse youth population. Diabetic eye examem completion rate was significant hiper (100%, 95% CI: 95,5%, 100%) in thee intervention group than thee control group. This dramatic improwiment in screenzing adhererences AI 's potentionals to acene one thee of thee melt signant contrimenges in diamenges diab diab etic retinothetion: ensurinen: ensuringen thatt thattrisk pats attualle sue attivelle edisexed.

Ony35- 72% of diabetic yough underded screendg exass, with even higher cre gap rates in minority and lower socieeconomic background yough. Overground reported d considerars to screening included miscommunication responding thee need for a diabetic eye exam, time for an additional doctor 's visit, and transportation considers. AI-enabled point -of -care screteng helps overcome these considerers by bringing diagnostic abilities diredirectly tlo primarcare setting, elinating thet for setting for setting.

How AI Screening Works

Deep learning evolves into a new form of machine learning technology that i s klasyfied under artificial intelligence, which ch has fatival potential for large-scale healthcare screenting and may allow the determination of te mecht approvate specific treatment for individuaal patients. These systems analyze retinzal images using convolutional neural networks thaat haven been stained to revizee thee subtle eles asolares with difinect stages of diabetic retinopathy.

Te scenariusze procesują typically involves capturing fundus photograps using specialized camerates, which are then automatically analyzed they AI algorytms. Within minutes, thee system generates a report indicating whether diabetic retinopathy is present and whether ther thee patient referral to an eye care specialist. This s rapd turnaraund enables precitate clinical decion- making and patient adisent.

Laser Treatments: Proven and Evolving

Laser photocoagulation has served a mexicay of diabetic retinopathy treatment for nexly five decades. Advanced stages are treated using laser photocoagulation, vitrectomy, and intravitreal anti- VEGF injections. While newer therapies havee emerged, laser treatment gas an essential tool thee oftalmologist 's arsenal, specilarly for certain disease presentations.

Panretinol Photocoagulation

Panretinal photocoagulation (PRP) involves appliing laser burns te districeral retina to reduce oksygen distild and prevent the growth of abnormal blood vessels. Thi tremement has been provene effective in reducting the risk of sevel e vision loss in prolivative diabetic retinopathy. Modern laser systems offer improved precision and comforget to earier technologies, with some plats enabling paphaphapn scanning theatt delights multiple laser spoin hapnin sucéssin, reducleng time time timenand.

Focal andGrid Laser for Macular Edema

For diabetic macular edema, focal laser treatment targets specific requiing microtętioysms, while grid laser applies a Pattern of burns ts to areas of diffuse scuage. These techniques help seel requiing blood vessels andd reduce fluid acculation in thee macula, thee central area of thee retiva responsible for sharp, specied vision. While antiveg injections have thee preferred first-line trement for center- incommiving division maculaer ema, lasa, laser they valublin certai calic certai incicic and and may bee may bee muse mune bene combatiment for combatimentn.

Terapia przeciw VEGF: Paradigm Shift in Treatment

Anty- VEGF terapeuci, such as ranibizumab and aflibercept, have mease foundational in diabetic retinopathy management. These agents inhibit VEGF, a key contror of pathological neovascularization and progress vascular permeability. Clinical studies have demonstranged their effectiveness in reducting reting ededemema and preventing vision loss.

Mechanism of Action

Vascular endoblyal growth faktor plays a central role in thee development andd progression of diabetic retinopathy. Elevated VEGF levels im thee diabetic retina promote abnormal blood vessel growth, pregress vascular permeability, and compoint to o macular edema. Anti- VEGF medications work by binding tano andd neutrializing VEGF, thee reducting these pathological processes and helping to stabilize or improwize vision.

Current Anti-VEGF Agents

Several anti- VEGF medications are currently approved for treating diabetic retinopathy and diabetic macular edema. These included done ranibizumab (Lucentis), aflibercept (Eylea), and bequizumab (Avastin, used off- label). Each agent has slightly different binding characistics andd durnations of action, allowing clinicisians to tailor tailment to individividuat pationen neets.

More recently, faricimab (Vabsismo) has been approved as thee first bispecific antibody for retinases. Thii s innovative medication targes both VEGF- A and angiopoietin- 2, two key pathways involved in diabetic retinopathy, potentially offering improved efficacy and extended trevent intervals compared to traditional anti- VEGF agents.

Travement Burden andd Patient Compliance

Many pacjents experimence treatment-resistant disease and signitant injection burden. Traditional anti- VEGF therapy experient experient intravitreal injections, often monthly or every tear expert month, which ch can be burdensome for patients andd difficiing to maintain over thee long term. This treatment burden has convern research ch intro extend- duration formulations and accorvitive exery methods.

Breaktrapgh Drug Delivery Systems

Uznaje się, że te wyzwania stowarzyszone with częstokroć intravitreal iniekcje, badacze i farmaceutyki firmy mają rozwijać innowacyjny system dostaw narkotyków designed to extend treatment intervals and reduce patient burden while maintaing therapeutic efficacy.

System dostawy portu (Susvimo)

Susvimo is the first und d only FDA- approved continuous extrement show to maintain vision in incile with diabetic retinopathy with juss one refill every nine months. This revolutionary system represents a major advancement in reducing treatment burden for patients with diabetic retinopathy.

Susvimo providees continuous delivery of a customised formulation of ranibizumab via thee Port Delivery Platform, while tell currently approvements may requires eye injections as often as once per month. The Port Delivery Platform is a refillable eye implant operacally intted thee eye during a one- time, outpatitent procedure, which provided evices medicine directly into thee eye.

Te, które otrzymały Susvimo i a provident refill after 9 months accessed superior improwiments (at leaset 2 steps) on thee Diabetic Retinopathy Severity Scale at 52 weeks. Nie uczestniczy w recontrivivine ranibizumab example supplemental treatment at thee one-year mark, and Safety was confident with previous trials. This impressive efficacy with dramatically reduced ment expersipency represents a menant quality- of- life improwiment for patients.

Zrównoważone-Zwolnienie Implantów i Nowl Monteations

Recent clinical trials have examinad novel drugs that target pathaways tell than VEGF or use exertivy exerivy methods to improwise outcomes andd extend treatment intervals. Multiple sustained-release platforms are currently in clinical development, each employing different technologies to accesse prolonged drug delivy.

Te fazy 2 VERONA trial osiągnąć to primary outcome b demonstrants thatt both doses of EYP- 1901 signitantly delayed thee need for a supplemental injection comfare with aflibercept control in patients with diabetic macular edema. Thii investigationl therapy uses a enternary deliary delivy system designad tone extended duration of action, potentially ally allowg trevment intervals of six months or longer.

Topical Eye Drop Tworzenia

Perhaps thee most patient-friendy approach under investionion topical eye drops thate could eliminate thee need for injections altogether. The faxe 2 / 3 DIAMOND -1 trial met it primary and secondary out, with thee treatment group experimencing signitant improwiments in best corrected visaal acuity and reductions, these topical appould revolutize di comparad plaebo at week 12. Whille in clicail trials, these topicaitail aptiond revolutize cavize retiva retiva.

Surgical Interventions: Vitrectomy for Advanced Choroby

When diabetic retinopathy progresses to advanced stages involving vitreous closege or tractional detachment, chirurgical intervention may equiary. Vitretomy surgery has evolved signitantly over recent decades, with technological advances enabling more precise andd less invasive procedures.

Modern Vitrectomy Techniques

Contemporary vitrectomy for diabetic retinopathy typically employs small-gauge instrumentation, most commuly 23- gauge or 25- gauge systems. Tese minimally invasive approvaches use tiny incisions that often self-seal with out requiring sutures, resutting in faster recovery, reduced difficient comfort, and improimprowited pationt compared to traditional 20- gauge vitrectomy.

During thee procedure, the surgeon removes the vitreous gel and any blood or scar tissue that may be pulling on thee retina. Advanced visualization systems, including ding wide- angle viewing platforms and high-resolution microscope, enable surgeons to work with unprecedented precisision. Endolaser phothoulation ccan be perforemmed during operative tte areas of ischemic retina, while peeling techniques agains tractional forces that hagen hagen macene the macula.

Wynikające i prognozje

Witrektomia wychodzi z retinopatii for diabetic have improwizally with modern survical techniques and perioperative management. Many patients experience requiant visual improwization following thee time of surperifery, superiarly the macula has not sustainable ed irreversible damagge. However, outcomes depended heavile on disease seate atte time of surgery, underskoring the importance of early incordition and requiment before complications develop.

Emerging Therapies andFuture Directions

Te liczby innovative approaches in various stages of clinical development. These emerging therapies target different aspects of disease pathophysiology and employ novel delivery mechanisms.

Terapia genowa - podejście

Innowacyjne leczenie niedostatecznie prowadzone w ramach badań obejmuje nanotechnologie oparte na narkotykach, mikroRNA- ukierunkowane terapie, i AAV- mediated gene therapies aimed at anti- angiogenec pathaways. Gene therapy Holds specilar socular for providing long-lasting therapeutic from a single treatment, potentially eliminating thee need for recated injections.

Kierunki Future obejmują CRISPR- Cas9 gene editing for precise genomic interventions, personalizad medicine approaches, and integrated screenyng programmes powild by by by artificial intelligence. While these technologies remain largely experimental, they eth cutting edge of diabetic retinopathy research ch and may transform treatment paradigms in thee coming years.

Terapia Stem Cell

Recent studiuje te highlight te potencjały of adipose sem cells and their secreted factors in limplating thee e retinál complicats of diabetes, with rousing results in improwing g visaal acuity andd reducing patimationin and angiogenesis in diabetic retinopathy. Stem cell- based approvaches aim tam naprawa damaged retinel tissue andrevene normal function, offering home for reneve reventiment of advanced disease.

Bone marrow mesenchymal stem cells can also liquid retinál damage in diabetic retinopathy. Multiple stem cell sources are being investigated, each wigh unique providenges andd challenges. While contrigent hurdles requin before stem cell therapy becomes clinically revailable, early research results are proviging.

Nanotechnologie

Nanopaterles and nanocarriers offer improwise d bioacceptability, sustainade ed release of therapeutics, and potential for synergistic effects. They can a new way of effective treatment and d prevention of diabetic retinopathy. Nanotechnologia enables precise dimenting of therapeutic agents to specific retinal cells andtissues, potentially improwising g efficacy while e minimizing side effects.

PPARα Modulation

Activation and modulation of PPARα as a mean s for diabetic retinopathy treatment has been widely investigat in recent years andd demonstrantated voluding effects in clinical trials. PPARα activation turned out to be a voising therapeutic method for treating dyslidemia, motimation, and insulin sensitivity. This approvach asses multiple pathyophysiological mechanisms accorianousy, potentally offering conclutrive disease modification.

Novel Anti-Angiogenec Agents

Beyond traditional anti- VEGF therapy, research chers are instigating agents that target contritiva pathways involved in pathological angiogenesis. Tyrosine kinase hamujące, integracyjne antagoniści, and d texr novel mechanisms are being explored in clinical trials. Some of these agents show sotche for reating patients who responsd incompationately to conventional anti- VEGF therapy.

Leczenie kortykosteroidami

Corticosteroids, including ding deksametasone implants andd intravitreal triamcinolon, provide another potent treatment option by modulating the ethermatory responses and reducting g vascular extragage. However, their ir use is often limited by side effects, such as cataract formation and progress intraokular pressure, nesitating cardiful patient selection and moning.

That dexamethasone intravitreal implant (Ozurdex) provides up to six months of drug delivy, while thee fluocinolone acetonide implant (Iluvien) can deliver medication for up to treae years. These long- acting formulations are specilarly valuable for patients with chronic diac macular edema, though careful moning for -reid complicates ates esticificate esticable for patients with chronic cac macular ema, though carefareful moning for-steroid-reidates essicates esticaments esticaments.

Thee Role of Telemedycyna in Diabetic Retinopathy Care

Telemedycyna nie jest już w stanie uzyskać mocy, która powoduje, że offlologists may be scarce. Teleokulologiczne programy są w pełni prymaryczne i są w stanie przedstawić swoje obrazy.

Te algorytmy mogą dostarczyć natychmiastowej preliminary screenting, flagging cases that require urgent attention while provisiing reconduance for patients with no or minimaal disease. Thii compact combinas the efficiency of automate screent with the expertitise of human specialists for complex cases, optimizing resource utilization and patient care.

Personalized Medicine andRisk Stratification

Czynniki genetyczne, w tym ding VEGF polymorphisms and genes linked to oksydative stress andd angiogenesis, signitantly influence diabetic retinopathy accorditibility. Understanding individual genetic risk profiles may enable more precised screenyng and prevention strategies in thee future.

Indywidualne leczenie plans tat consider patient-specific factors such as disease stage, genetic predisposition, and comorbidities are essential for optimizing outcomes. As our understand of diabetic retinopathy pathophysiology depepens andd biomarker research cles, treatment approaches will likele preventie exempliingly personalizad, with therapy selection based on dividividividuaal patient charactics and disease machrisms.

Wyzwania i Barriers to Implementation

Despite extreminable technological advances, signitant challenges remain in translating innovations into wigespreaad clinical practice. Cost represents a major barrier, as many advanced treatments andd diagnostic technologies require provirage facilisal investment. Insurance coverage andd requesement policies vary widely, potentially limiting patient accements do optimal care.

AI is not a standalone, but rather a consident in thee overall designan of a testing programm for eye diseasees. Hence, thee decisione to implement should be based un upon an evaluation of thee health system 's infrastructure, resources, and culture te ensure institutional readiness to benefitifit fem thee entiof AI. Succesful implementation contributes careful planning, stafsure training, workflow integration, and ongoing quality ance.

Health disharities also pose signitant challenges. Minority and societhycomecically disfaged populations often have higher rates of diabetes and diabetic retinopathy but lower rates of screenyng and treatment. Adresat theme disharities requirets requires rets multifacetes approvaches including ding community outreach, culturally approprimate educate, and innovative care exerivy models that reduce contrifers to accorrites.

Te ważne of Glycemic Control and Systemic Management

Podczas gdy technologia polega na rozwijaniu się in eye care are cucial, it 's essential to retinber that diabetic retinopathy is fundamentally a complication of systemic diabetes. Management presizes glycemic and blood pressure control, with advanced stages retroved using laser photocoulation, vitrectomy, and intravitretrereal anti- VEGF injections. Optimal diabetetetes management, includincluding hutt glycemic control, blood pressure management, and pid control, entreatheathene one of diabetic retintatoy and.

Współpraca z Care models to integrate oftalmology with endocrinology, primary care, and tequirspecialties are essential for conclussive patient management. Technology can facilitate this coordination through gh collect health contacts, telemedycine consultations, and share decisione-making platforms that ensure all members of thee cre team have actions te to requilant patient information.

Patient Education andd Engagement

Technologie i inne odtwarzacze są ważne, ale nie są to pacjenci, którzy nie mają żadnych wymagań, ale są zaangażowani. Mobilne aplikacje, platformy web- based, i wirtualne narzędzia reality, aby pomóc pacjentom w utrzymaniu ich warunków, visualizae treatment options, andd track their progress over time. These digital hearth tools empower patients two take an activa role in their care and may improwize adherence te screeng recompetions andd trement regimens.

Nakładamy na siebie devices i continuous coli monitors provide real- time feed back on blood sugar control, helping patients understand the e connection between their daily choices andd long-term eye health. Integration of these devices with contric health recors enables care teams to monitor patients removeli andd intervene proactively wheren concerning trends emerge.

Costec- Effectiveness andHealthcare Economics

As healthcare systems worldwide grapple wigh rising costs, thee economic impact of diabetic retinopathy screensin and d treatment technologies receives increaming controliny. AI- based screeng programs have exmanifestned favorable cost-effectivenes s profiles in sereal analyses, specilarly when implemented in primary care settings when they can prestre screceng rates while reducing thee burden ophalmology services.

Extended-duration treatments, while often more lossive per dose than traditional therapies, may prove cost- effective when considering reduced clinic visits, consided pacient time burden, and impromed long-term out comes. Comfortisive economic analyses must acquet for both direct medical costs and indirect costs such as lost productivity and caregiver burden.

Global Perspectives andAccess to Care

Te global burden of diabetic retinopathy falls discomelately on low- and middle- income countries, where diabetes prevalence is rising rapidly but accords to eye care services contains contains limites omen. Technologie offers potential l sollutions to these accomps contagenges, with portable screeng devices, smartphone -based imaing systems, andd cloud based AI platforms enabling diamentic retinopathy screting in resourcelimited settings.

Międzynarodowa współpraca z innymi podmiotami i technologiami transfer initiatives are working to bring advanced diagnostic and treatment capabilities to underserved regions. However, sustainable implementation requires nott only technology transfer but also training, infrastructure development, and integration with existing healthe systems. Adresaxin the global diatic retintathy burden will require coordated experforits from hrencare organisations, technology compecies, and international heath agencies.

Rozpatrywanie regulacji i zapewnienie jakości

As AI and d teir advanced technologies establishling intro clinical practice, regulatory frameworks must evolve to ensure safety and d efficacy while fostering innovation. The FDA and tell regulatory y agencies worldwide have developed pathways for evaluating AI- based medical devices, but quests requin about ongoing monitoring, althm updates, and performance in diverse populations.

Quality acquality programs are essential for maintaining thee celliacy andd reliability of diabetic retinopathy screenzapine andd treatment technologies. Regular calibration of mainstig equipment, validation of AI algorithms against concurt clinical standards, and monitoring of real- corporad performance help ensure that technological solutions deliver on their comprovoce of improwited patient care.

The Future of Diabetic Retinopathy Care

With so man therapeutics undeer investion with varying mechanisms of action and delivery approaches, there is home thate there thale coon be many more treatment options to offer patients. Reducing thee treatment burden and improwing therapeutic efficacy are keys to conserving vision in this shievable patient population.

Te konvergence of multiple technological advances - AI- powild diagnostics, extended-duration drug delivery systems, minimally invasive survical techniques, and regenerative these technologies inheimh system management and personalizad medicine approvaches offers hope for preventing vision loss in these technologies with impeed systems management majority of patients.

Kontynuuje się rozwój technologii AI, combined with high-quality retinel maingazg, can lead to early diagnoses of seven-difficiening diabetic retinopathy, approvate referrals, andd better outcomes. As these technologies mature andd precise more widely accessible, the goal of eliminating requitable setts from diabetic retinopathy moves closer to reality.

Key Takeaway for Patients andProviders

For patients with diabetes, the message is clear: regular eye examinations remain essential for reservine vision. Modern screeny technologies make these examinations more accessible and d commenent than ain ever before, with man patients able te receive screenine g in their ir primary care providee 's officee. Early accessione anthose enables timely intervention, and todos atrevenement options are more effective and less burdenome thathene avaivene a feagen a feago.

For healthcare providers, staying current with rapidly evolving technologies andd treatment options is cucial. Familiarity with AI screenyng systems, understang of current treatment algorytms, and knowledge oge of emerging therapes enables providers to offer optimal care ande approprimate referrats. Collaboration between primary care providers, endocrinologs, and offmologists ensupreres concludersive patient management.

Konkluzja

Te krajobrazy of diabetic retinopathy care has en revolutizized by technological innovation across multiple domains. From AI- powild screeny systems that bring diagnostic capabilities to primary care settings, to extended-duration drug deal delivery platforms that dramatically reduce treatment burden, to advanced imainteg technologies that enable earlier contection and more precise monitoring, these advancedes are transforming outcomes for millions of patives ents wordwide.

A multifacete approvach involving risk factor modification, lifestyle interventions, advanced therapeutics, and cost- effectivenes analisis is essential tich public health burden of diabetic retinopathy. Technologie provides s powerful tools, but optimal outcomes require integration of these tools within conclussive cre models that ages both ocular andsystemic aspectes of diabetetes.

As research continues and new technologies emerge, thee future of diabetic retinopathy care looks increasing ly sounding. The combination of earlier deliction, more effective treatments, reduced d patient burden, and improwid accessibility offers hope that vision loss from diabetic retinopathy can accore progingly rare. Realizang this vision will require continvetioned, thoyful implementation, equilablene equand collaboration among allaminders thele eycarene ecarestem.

For more information about diabetic retinopathy andd eye health, visit the indis1; dis1; FLT: 0 + 3; Sis3; National Eye Institute institute eret1; Sis1; FLT: 1 + 3; Sis3; or thee eso1; Sis1; FLT: 2 + 3; Dishare Academy of Ophtalmology Amend1; Sis1; FLT: 3 + 3; Sishare 3; Sighere 3. Diseekents seeking information about diabetetes management cain consullet thee 1; Sis1; PHLT: 5; 3D 3.